Trial Profile
A randomized phase ll study consistiong S-1+DTX and S-1+CDDP for advanced/metastatic gastric cancer without any mesurable lesions (HERBIS-3).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Feb 2019
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Cisplatin
- Indications Gastric cancer
- Focus Therapeutic Use
- Acronyms HERBIS-3
- 20 Feb 2019 Status changed from active, no longer recruiting to completed.
- 18 Aug 2012 Actual initiation date changed from 1 Aug 2011 to 22 Aug 2011 added as reported by University Hospital Medical Information Network - Japan
- 22 Nov 2011 Status changed from not yet recruiting to recruiting as reported by University Hospital Medical Information Network - Japan.